Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering. Stockholders are advised to ensure they own Cytori's stock as of 4:00 PM ET on Tuesday, May 17, 2016 to be considered a stockholder of record on Friday, May 20, 2016. Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below.

Under the rights offering, Cytori will distribute one non-transferable subscription right for each share of common stock held on the record date. Each right will entitle the holder to purchase one unit at the subscription price, with each unit composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock.

The subscription rights are non-transferrable and may only be exercised during the anticipated subscription period of Monday, May 23, 2016 through 5:00 PM ET on Thursday, June 9, 2016, unless extended.

The expected calendar for the rights offering is as follows:

• Tuesday, May 17, 2016, Ownership Day – in order to be considered a stockholder of record on Friday, May 20, 2016, shares should be acquired by this date.
• Friday, May 20, 2016 Record Date
• Monday, May 23, 2016 Subscription Period Begins
• Thursday, June 9, 2016 Subscription Period Ends 5:00 PM ET*
  
  * Unless extended in Cytori's sole discretion
  

Holders who fully exercise their basic subscription rights will be entitled, if available, to subscribe for an additional amount of units that are not purchased by other stockholders, on a pro rata basis and subject to ownership limitations.

Cytori has engaged Maxim Group LLC as dealer-manager for the rights offering. Questions about the rights offering or requests for copies of the prospectus may be directed to Broadridge Corporate Issuer Solutions, Cytori's information agent for the rights offering, by calling (855) 793-5068 (toll-free); or Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

A registration statement relating to the securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The rights offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the written prospectus for the rights offering may be obtained, when available, from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note Relating to Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements." The words "expects," "believes," "potential," "possibly," "estimates," "may," "could" and "intends," as well as similar expressions, are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that statements which are not strictly historical statements, including, without, statements regarding conduct and timing of our proposed rights offering, are forward looking statements. Forward looking statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include our financial condition (including cash runway, our ability to access additional capital to fund our business, and our expectation that we will continue to incur losses at least in the near-term); clinical and regulatory uncertainties (including conduct and results of our clinical trials and investigator-initiated clinical trials using our technology, and challenges in obtaining and maintaining regulatory clearances and approvals for our products); market acceptance of our technologies, including introduction of superior technologies into our anticipated markets; our ability to compete with larger, better financed competitors; dependence on third party clinical investigators, suppliers and manufacturers; our ability to commercialize and sell products; our abilities to regain and maintain compliance with NASDAQ listing standards; our compliance with laws, rules and regulations applicable to our business; our ability to attract and retain skilled personnel; our volatile stock price, and; our ability to protect and expand our intellectual property rights, and other risks and uncertainties described under the “Risk Factors” in Cytori's Securities and Exchange Commission Filings. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any changes in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our registration statement on Form S-1 for the proposed rights offering, as well as our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160517005678/en/